Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study
暂无分享,去创建一个
J. Blay | S. Piperno-Neumann | L. Brugières | M. Le Deley | N. Entz-Werlé | N. Corradini | J. Gentet | P. Marec-Berard | M. Tabone | R. Couderc | H. Pacquement | A. Chevance | C. Lervat | M. Selva | C. Mahier-Ait Oukhatar
[1] J. Blay,et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.
[2] P. Rossen,et al. Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients , 2014, Acta oncologica.
[3] Yanfeng Zhuang,et al. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis , 2014, Tumor Biology.
[4] Jiong Hu,et al. Clinical predictive value of serum angiogenic factor in patients with osteosarcoma. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[5] M. Sharma,et al. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: a prospective study , 2012, International Orthopaedics.
[6] H. Rosenthal,et al. Expression of Vascular Endothelial Growth Factor correlates with the advance of clinical osteosarcoma , 2012, International Orthopaedics.
[7] P. Casali,et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] N. Theera-Umpon,et al. Relationships between serum biomarker levels and clinical presentation of human osteosarcomas. , 2011, Asian Pacific journal of cancer prevention : APJCP.
[9] R. Morgan,et al. Antiangiogenic effects of zoledronate on cancer neovasculature. , 2011, Future oncology.
[10] Jianda Xu,et al. Difference in Pre- and Postchemotherapy Vascular Endothelial Growth Factor Levels as a Prognostic Indicator in Osteosarcoma , 2011, The Journal of international medical research.
[11] K. Szamotulska,et al. A prognostic evaluation of vascular endothelial growth factor in children and young adults with osteosarcoma , 2011, Pediatric blood & cancer.
[12] Xiao-Li Liu,et al. Expression of b‐FGF and endostatin and their clinical significance in human osteosarcoma , 2010, Orthopaedic surgery.
[13] P. Terrier,et al. Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial. , 2010, Current oncology.
[14] G. Schinzari,et al. Neoadjuvant multidrug chemotherapy including High-Dose Methotrexate modifies VEGF expression in Osteosarcoma: an immunohistochemical analysis , 2010, BMC musculoskeletal disorders.
[15] G. Machak,et al. Endostatin, Placental Growth Factor, and Fibroblast Growth Factors-1 and -2 in the Sera of Patients with Primary Osteosarcomas , 2009, Bulletin of Experimental Biology and Medicine.
[16] V. Sreenivas,et al. VEGF expression as a prognostic marker in osteosarcoma , 2009, Pediatric blood & cancer.
[17] T. Yamashita,et al. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. , 2009, The Journal of bone and joint surgery. British volume.
[18] F. B. Sørensen,et al. Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation , 2009, Sarcoma.
[19] T. Yamashita,et al. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin , 2007, Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association.
[20] D. Vanel,et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. , 2007, European journal of cancer.
[21] E. T. Ek,et al. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? , 2006, Oncology reports.
[22] P. Pickkers,et al. VASCULAR ENDOTHELIAL GROWTH FACTOR IS INCREASED DURING THE FIRST 48 HOURS OF HUMAN SEPTIC SHOCK AND CORRELATES WITH VASCULAR PERMEABILITY , 2005, Shock.
[23] D. Pérol,et al. Metastatic osteosarcoma at diagnosis , 2005, Cancer.
[24] M. Semik,et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Kreuter,et al. Prognostic relevance of increased angiogenesis in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Mikulic,et al. TUMOR ANGIOGENESIS AND OUTCOME IN OSTEOSARCOMA , 2004, Pediatric hematology and oncology.
[27] P. Rutkowski,et al. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: Correlations with local tumor extent and prognosis , 2003, Journal of surgical oncology.
[28] P. Leavey,et al. Lack of Prognostic Significance of Intratumoral Angiogenesis in Nonmetastatic Osteosarcoma , 2001, Journal of pediatric hematology/oncology.
[29] Martin A. Koschat,et al. Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. , 2001, Medical and pediatric oncology.
[30] G. Leverger,et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[31] F. Higashino,et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] Y. Oshika,et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. , 1999, European journal of cancer.
[33] H. Joensuu,et al. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] E. Ingham,et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.
[35] É. Lepage,et al. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? , 1997, Clinical Cancer Research.
[36] M. Toi,et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] J. Richie,et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. , 1994, Journal of the National Cancer Institute.
[38] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[39] X. Yu,et al. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis , 2013, Tumor Biology.